GLOBAL DPP-4 INHIBITORS Market 2022-2028

GLOBAL DPP-4 INHIBITORS Market 2022-2028

Current Industry Analysis and Growth Potential Outlook

The global Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Industry is growing at a CAGR of 3.5% during the forecast period (2021-2028). The DPP-4 inhibitors market was valued at around $7.2 billion in 2021. The industry is driven by the rise in incidence and prevalence of diabetes type-2 across the globe. The three main types of diabetes are termed type 1 diabetes, type 2 diabetes, and gestational diabetes (diabetes arising during pregnancy). Type 2 diabetes represents more than 90% of global diabetes. According to International Diabetes Federation (IDF), approximately 463 million adults (20-79 years) were living with diabetes in 2021 and by 2045 this will rise to 700 million. Of which, 374 million people are at increased risk of developing type 2 diabetes. In 2021, diabetes was the direct cause of 1.5 million mortality and 2.2 million mortalities were attributable to high blood glucose in 2012 as per World Health Organization (WHO). As DPP-4 inhibitors are a class of prescription medicines that are used to control high blood sugar in adults with type 2 diabetes, it has been significantly used across the globe. Further, growth in the geriatric population and obesity also rise the risk of developing heart disease, hypertension, type 2 diabetes, and obstructive sleep apnea which is expected to contribute to market growth.

The main pathogenesis of type 2 diabetes mellitus includes insulin resistance and pancreatic islet dysfunction. In type 2 diabetes, the body becomes resistant to insulin, secretion of insulin becomes impaired, or both. Hence, there is a continuous demand for recommended drugs in case of insulin resistance. Metformin, which attenuates insulin resistance, has been recommended as the first-line anti-diabetic medication. However, DPP-4 inhibitors are second-line treatments for type 2 diabetes and are a relatively new class of oral diabetes drugs. Also known as gliptins include sitagliptin, saxagliptin, linagliptin, alogliptin, and others and are usually prescribed for people with type 2 diabetes who have not responded well to drugs such as metformin and sulphonylureas.

An increase in clinical trials on the DPP-4 inhibitors will also boost the market growth during the forecast period. Presently dominating drug JANUVIA (sitagliptin) by Merck & Co., has significantly in demand, hence, the company is exploring new opportunities in the area. In June 2021, Merck announced new data from the Comparative Trials with Sitagliptin (CompoSIT) clinical trials with JANUVIA (sitagliptin). In the CompoSIT-I study, initiation of insulin therapy while continuing treatment with JANUVIA resulted in greater blood glucose reductions and more patients reaching the A1C goal compared to those who discontinued JANUVIA.

Market Segmentation

Global DPP-4 inhibitors market is segmented based on drug type that covers Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Alogliptin, Teneligliptin, and Others (Anagliptin).

Regional Analysis

The global DPP-4 inhibitors market is segmented into North America (the US and Canada), Europe (Germany, UK, France, Italy, Spain, and Rest of Europe), Asia-Pacific (China, India, ASEAN, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World. North America region held a significant market share.

Company Overview

The prominent players functioning in the global DPP-4 inhibitors market include Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Merck & Co., Eli Lily & Co., LG Life Sciences Ltd., Novartis AG, and Takeda Pharmaceutical Co. among others. Merck held the highest market share of 49.6% in the DPP-4 market in 2021 and is expected to maintain its position till 2022. After that, it may witness a decline in market share, due to the expected launch of a generic version of Sitagliptin in 2022. These key manufacturers are adopting various strategies such as new product launches and approvals, mergers and acquisitions, partnerships and collaborations, and many others to thrive in a competitive environment. For instance, in September 2021, the Zydus Cadila arm receives US FDA approval for sitagliptin base 25, 50, and 100 mg tablets. Zydus’ Sitagliptin base contains the active moiety sitagliptin in a different form than used in the branded reference product, Januvia (sitagliptin phosphate). The drug is a generic version of Merck & Co’s Januvia/Janumet (sitagliptin).